gh receptors
Recently Published Documents


TOTAL DOCUMENTS

64
(FIVE YEARS 0)

H-INDEX

22
(FIVE YEARS 0)

2019 ◽  
Vol 20 (21) ◽  
pp. 5264 ◽  
Author(s):  
Bolamperti ◽  
Guidobono ◽  
Rubinacci ◽  
Villa

Growth hormone (GH) is best known for its prominent role in promoting prepubertal growth and in regulating body composition and metabolism during adulthood. In recent years, the possible role of GH in the modulation of mesenchymal stem cell (MSC) commitment has gained interest. MSCs, characterized by active self-renewal and differentiation potential, express GH receptors. In MSCs derived from different adult tissues, GH induces an inhibition of adipogenic differentiation and favors MSC differentiation towards osteogenesis. This activity of GH indicates that regulation of body composition by GH has already started in the tissue progenitor cells. These findings have fostered research on possible uses of MSCs treated with GH in those pathologies, where a lack of or delays in bone repair occur. After an overview of GH activities, this review will focus on the research that has characterized GH’s effects on MSCs and on preliminary studies on the possible application of GH in bone regenerative medicine.


2019 ◽  
Vol 45 (1) ◽  
pp. 38-39
Author(s):  
V. A. Gubkina ◽  
T. S. Kamynina ◽  
E. V. Kornilova ◽  
A. V. Dreval

Pseudohypoparathyroidism (PGPT) - Albright's hereditary osteodystrophy is a sex-related disease rarely seen in medical practice. Inherited by the dominant type. It is caused by insensitivity of the kidneys and bones to parathyroid hormone (PG), which is secreted in normal or slightly elevated amounts [6, 10]. GH may not have a specific effect on cells due to pathology of GH receptors, impaired expression of information RNA synthesis by an unchanged hormone-receptor complex, the presence of pathological components of adenylate cyclase, pathological AMP-dependent protein kinase, or a defect in the synthesis of kinase substrates in the presence of circulating GH antagonists [5, 10 ].


2019 ◽  
Vol 116 (15) ◽  
pp. 7449-7454 ◽  
Author(s):  
Fei Fang ◽  
Xuanming Shi ◽  
Michael S. Brown ◽  
Joseph L. Goldstein ◽  
Guosheng Liang

When mice are subjected to 60% calorie restriction for several days, they lose nearly all of their body fat. Although the animals lack energy stores, their livers produce enough glucose to maintain blood glucose at viable levels even after a 23-hour fast. This adaptation is mediated by a marked increase in plasma growth hormone (GH), which is elicited by an increase in plasma ghrelin, a GH secretagogue. In the absence of ghrelin, calorie-restricted mice develop hypoglycemia, owing to diminished glucose production. To determine the site of GH action, in the current study we used CRISPR/Cas9 and Cre recombinase technology to produce mice that lack GH receptors selectively in liver (L-Ghr−/− mice) or in adipose tissue (Fat-Ghr−/− mice). When subjected to calorie restriction and then fasted for 23 hours, the L-Ghr−/− mice, but not the Fat-Ghr−/− mice, developed hypoglycemia. The fall in blood glucose in L-Ghr−/− mice was correlated with a profound drop in hepatic triglycerides. Hypoglycemia was prevented by injection of lactate or octanoate, two sources of energy to support gluconeogenesis. Electron microscopy revealed extensive autophagy in livers of calorie-restricted control mice but not in L-Ghr−/− mice. We conclude that GH acts through its receptor in the liver to activate autophagy, preserve triglycerides, enhance gluconeogenesis, and prevent hypoglycemia in calorie-restricted mice, a model of famine.


2017 ◽  
Vol 6 (8) ◽  
pp. R171-R181 ◽  
Author(s):  
Kennett Sprogøe ◽  
Eva Mortensen ◽  
David B Karpf ◽  
Jonathan A Leff

The fundamental challenge of developing a long-acting growth hormone (LAGH) is to create a more convenient growth hormone (GH) dosing profile while retaining the excellent safety, efficacy and tolerability of daily GH. With GH receptors on virtually all cells, replacement therapy should achieve the same tissue distribution and effects of daily (and endogenous) GH while maintaining levels of GH and resulting IGF-1 within the physiologic range. To date, only two LAGHs have gained the approval of either the Food and Drug Administration (FDA) or the European Medicines Agency (EMA); both released unmodified GH, thus presumably replicating distribution and pharmacological actions of daily GH. Other technologies have been applied to create LAGHs, including modifying GH (for example, protein enlargement or albumin binding) such that the resulting analogues possess a longer half-life. Based on these approaches, nearly 20 LAGHs have reached various stages of clinical development. Although most have failed, lessons learned have guided the development of a novel LAGH. TransCon GH is a LAGH prodrug in which GH is transiently bound to an inert methoxy polyethylene glycol (mPEG) carrier. It was designed to achieve the same safety, efficacy and tolerability as daily GH but with more convenient weekly dosing. In phase 2 trials of children and adults with growth hormone deficiency (GHD), similar safety, efficacy and tolerability to daily GH was shown as well as GH and IGF-1 levels within the physiologic range. These promising results support further development of TransCon GH.


Endocrinology ◽  
2017 ◽  
Vol 158 (5) ◽  
pp. 1406-1418 ◽  
Author(s):  
Rikke Hjortebjerg ◽  
Darlene E. Berryman ◽  
Ross Comisford ◽  
Stuart J. Frank ◽  
Edward O. List ◽  
...  

Endocrinology ◽  
2015 ◽  
Vol 156 (5) ◽  
pp. 1620-1622 ◽  
Author(s):  
Andrzej Bartke ◽  
John J. Kopchick

Studies of the effects of GH and the mechanisms of its actions frequently use rats or mice and various recombinant human GH preparations. Authors of many of these studies appear unaware of the fact that, in rodents, human GH signals through both GH and prolactin (PRL) receptors; thus, treatment with human GH is equivalent to a combined treatment with GH and PRL. GH receptors and PRL receptors are present in multiple cell types. Importantly, PRL exerts major effects on brain neuroendocrine action, female and male reproduction, metabolism, body composition, immune responses, and a host of other functions; thus, treatment of rodents with recombinant human GH could affect these important physiological parameters.


2014 ◽  
Vol 41 (1) ◽  
pp. 51-60 ◽  
Author(s):  
Tomás Horacio Delgadin ◽  
Daniela Irina Pérez Sirkin ◽  
María Paula Di Yorio ◽  
Silvia Eda Arranz ◽  
Paula Gabriela Vissio

Author(s):  
Fahad Zadjali ◽  
Ruyman Santana-Farre ◽  
Mercedes Mirecki-Garrido ◽  
Ewa Ellis ◽  
Gunnar Norstedt ◽  
...  

AbstractLiver X receptor (LXR) agonists have been shown to influence the development of hyperlipidemia and atherosclerosis in mouse models. It has also been demonstrated that some LXR agonists can cause hepatic steatosis in experimental animals. Growth hormone (GH) is known to regulate hepatic metabolism and the absence of hepatic GH receptors (GHR) leads to hepatic steatosis. In this study, we analyzed whether the actions of LXR agonists could involve interference with GH signaling. We showed that LXR agonists impair GH signaling in hepatocytes. LXR agonist treatment attenuated GH induction of suppressor of cytokine signaling 2 (


Endocrinology ◽  
2009 ◽  
Vol 150 (8) ◽  
pp. 3627-3636 ◽  
Author(s):  
Evelien F. Gevers ◽  
Matthew J. Hannah ◽  
Michael J. Waters ◽  
Iain C. A. F. Robinson

GH has physiological functions in many tissues, but the cellular targets for direct effects of GH remain ill defined in complex tissues such as the growth plate in which the contribution of direct vs. indirect actions of GH remains controversial. The Janus kinase (Jak)-signal transducer and activator of transcription (STAT)-5 pathway is activated by GH, so we developed a method to visualize nuclear Stat5b and phosphorylated Stat5 in single cells in response to a pulse of GH. Hep2 cells did not show a Stat5 phosphorylation (pY-Stat5) response to GH except in cells transfected to express GH receptors. ATDC5 cells express GH receptors and showed GH-induced pY-Stat5 responses, which varied with their state of chondrocyte differentiation. In vivo, Stat5b+ve nuclei were seen in the resting and prehypertrophic chondrocytes of the growth plate. After a single ip pulse of human GH or mouse GH, but not prolactin, pY-Stat5 responses were visible in cells in the resting zone and groove of Ranvier, 10–45 min later. Prehypertrophic chondrocytes showed no pY-Stat5 response to GH. GH target cells were also identified in other tissues, and a marked variability in spatiotemporal pY-Stat5 responses was evident. Endogenous hepatic pY-Stat5 was detected in mice with intact GH secretion but only during a GH pulse. Fasting and chronic exposure to GH attenuated the pY-Stat5 response to an acute GH injection. In conclusion, pY-Stat5 responses to GH vary in time and space, are sensitive to nutritional status, and may be inhibited by prior GH exposure. In the growth plate, our data provide direct in vivo support for an early role of GH to regulate the fate of immature chondrocytes.


Sign in / Sign up

Export Citation Format

Share Document